Fuda Cancer Hospital
| China | Turkey | Austria | |
| Halcyon | - | from $5,400 | - |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Patients choose China for nasopharyngeal cancer care due to the country's high case volume and clinical expertise. Chinese oncology centers manage nearly half of global cases annually. This experience allows surgeons and radiation oncologists to implement highly refined, standardized protocols. These specialized facilities often report 5-year survival rates exceeding 80%.
Bookimed Expert Insight: Data shows that centers in Guangzhou and Xiamen offer a significant experience advantage for head-and-neck cancers. Fuda Cancer Hospital has treated over 30,000 international patients using specialized minimally invasive tools. Dr. Liu Shi Xin in Xiamen is a State Council Special Government Allowance recipient. These credentials signal a level of expertise rarely found in regions where nasopharyngeal cancer is rare.
Patient Consensus: Patients emphasize that since this cancer is rare elsewhere, they seek Chinese teams for their routine expertise. Many note it is critical to find a center experienced in sparing salivary glands and cranial nerves during radiation.
China reports a 5-year survival rate for nasopharyngeal cancer (NPC) that meets or exceeds Western benchmarks in top-tier centers. Specialized facilities utilize high patient volumes and advanced radiotherapy to achieve these results. Survival outcomes globally depend significantly on early detection and modern radiation workflows.
Bookimed Expert Insight: Patient volume is a major quality signal for this specific cancer. Centers like Fuda Cancer Hospital have served over 30,000 international patients. This high throughput allows surgeons to refine complex techniques like NanoKnife and cryosurgery. Choosing a facility with massive yearly caseloads often leads to better survival outcomes than smaller clinics.
Patient Consensus: Patients note that specializing in head-and-neck oncology is vital for recovery. They often emphasize that centralized referral to high-volume centers helps catch the disease at earlier, more treatable stages.
Definitive Intensity-Modulated Radiotherapy (IMRT) is the gold standard for non-metastatic nasopharyngeal cancer in China. Specialists often combine it with systemic chemotherapy for advanced stages. This radiation-based approach yields 5-year survival rates exceeding 90% for stage I patients within Chinese oncology centers.
Bookimed Expert Insight: While most international protocols focus solely on radiation, Chinese centers like JCI-accredited Fuda Cancer Hospital emphasize specialized expertise in integrating minimally invasive therapies. Our data shows that high-volume providers often favor doctors with specific certifications, such as Dr. Liu Shi Xin, who holds multiple leadership roles in the Chinese Society of Clinical Oncology. This deep specialization in precision radiotherapy is crucial given that Chinese protocols are among the most aggressive globally due to high regional incidence.
Patient Consensus: Patients note that while the aggressive radiation-based approach is effective, prep for taste loss and severe mouth dryness is essential. Many recommend starting nutritional planning early to manage weight loss during the intensive treatment protocol.
Advanced treatments for nasopharyngeal cancer in China include PD-1 inhibitors like toripalimab and sintilimab. These immunotherapies are often paired with chemotherapy or precision radiation. JCI-accredited facilities offer next-generation ablation such as NanoKnife and cryosurgery. Chinese oncology centers maintain high 5-year survival rates through these multimodal protocols.
Bookimed Expert Insight: Data shows that Guangzhou hospitals often prioritize combining immunotherapy with microwave hyperthermia or vascular interventional therapy. Fuda Cancer Hospital has treated over 30,000 international patients using these combined minimally invasive methods. This multi-pronged approach is particularly effective for late-stage cases where traditional surgery is not viable. Doctors like Professor Liu Shi Xin also integrate precision radiotherapy to improve outcomes in thoracic and head-and-neck malignancies.
Patient Consensus: Patients emphasize that treatment plans are highly individualized based on EBV DNA markers and tumor response. Many note that advanced radiation delivery is just as critical as immunotherapy for long-term health.
Minimally invasive surgery is a viable option for recurrent nasopharyngeal cancer in China. It depends on the tumor location and prior radiation history. Specialists often use endoscopic transnasal approaches to remove small, localized recurrences. This avoids large incisions while preserving vital skull base structures.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital demonstrate a unique focus on specialized non-drug therapies. They apply over 10 types of minimally invasive treatments, including vascular intervention and microwave hyperthermia. This variety allows doctors to treat advanced cases where standard chemotherapy may have already failed.
Patient Consensus: Patients note that prior radiation often makes tissues fragile. They emphasize that endoscopic skull base surgery is complex and requires highly experienced surgical teams.
Chinese oncology centers reduce radiation side effects by combining precision radiotherapy with Traditional Chinese Medicine to protect healthy tissue. High-volume facilities utilize Intensity-Modulated Radiotherapy and adaptive planning to sculpt beams around tumors. This approach minimizes damage to salivary glands and nearby vital organs.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in Chinese oncology. Fuda Cancer Hospital has served over 30,000 international patients. This high volume allows specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital to refine immobilization and toxicity tracking. Centers with such extensive experience often maintain more consistent protocols for managing acute side effects.
Patient Consensus: Patients note that while side effects like dry mouth and fatigue still occur, precision techniques make them more manageable. They emphasize that long-term preservation of speech and swallowing function is the primary goal of these advanced protocols.